The molecular characterization of cerebral microvessels in experimental disease models has been hindered by the lack of a standardized method to reproducibly isolate intact cerebral microvessels, with consistent cellular compositions, and without the use of enzymatic digestion, which causes undesirable molecular and metabolic changes.
INTRODUCTION
The cerebrovascular endothelium is a highly specialized vascular bed, which, in coordination with pericytes, vascular smooth muscle cells and glial cells forms a physical, transport and metabolic barrier (the blood brain barrier), maintains an anticoagulant and anti-inflammatory state, and regulate microcirculatory flow in order to meet neuronal demands and maintain homeostasis. Increasing preclinical and clinical evidence indicate that these fundamental functions of the endothelium are severely compromised in cerebrovascular and neurodegenerative diseases and significantly contribute to the exacerbation of neuronal injury in these conditions [1] [2] [3] [4] [5] . In addition, the therapeutic potential of the cerebrovascular endothelium is also well established, since it is positioned right at the interface between blood and brain parenchyma. However, despite extensive research, our understanding of the molecular mechanisms underlying cerebral microvascular dysfunction is still very limited.
Working towards this goal, several studies have attempted to characterize the molecular signature of the cerebrovascular endothelium by transcriptome and proteome profiling of isolated cerebral endothelial cells or mural cells [6] [7] [8] [9] . These approaches have allowed the identification of molecules enriched in the cerebrovascular endothelium compared to the endothelium of other organs or to other components of the neurovascular unit. In order to investigate the activation of signaling pathways upon pharmacological treatments or upon ischemic or inflammatory challenge, numerous in vitro studies with cultured brain endothelial cells have been conducted 2, 10, 11 . However, both the unique phenotype and molecular signature of the endothelium from specific organs are lost upon isolation of the cells from their tissue microenvironment, deprivation from blood flow and in vitro culture 12, 13 . Such protocols also prohibit the accurate study of junctional protein expression, post-translational modifications and subcellular localization in health and disease states within a living organism. For all these reasons, in order to conduct the molecular characterization of cerebral microvessels in disease models or upon pharmacological treatments the ability to study the intact microvasculature -isolated from the brain parenchyma while retaining the integrity of intercellular connections between the endothelium and mural cells -is a vitally useful tool. Various methods have been used to isolate microvessel fragments preserving the interactions of the endothelium with mural cells. Many of these methods use enzymatic digestion to achieve purity and consistency between preparations 14 15 , causing undesirable molecular and metabolic changes, compromising RNA and protein integrity and impairing the ability to detect low abundance transcripts, changes in gene expression or the activation of signaling pathways. In order to overcome these challenges, we have established a method for mouse cortical microvessel isolation (Figure 1 ), by combining, optimizing and supplementing various previously published protocols 16,17 11 . The protocol described in this article yields intact microvessel fragments (diameter <50 µm, 89.3% 3-5 µm) with consistent populations of discrete blood-brain barrier components (endothelial cells, pericytes and astrocyte end feet) without a requirement for enzymatic digestion ( Figure 2 ), retaining high RNA integrity ( Figure 3 ) and protein postranslational
modifications. We subsequently demonstrate that, the described protocol can be applied to quantify changes in gene expression in a disease model (stroke) 18 ( Figure 4 ) and the activation of signalling pathways in mice subjected to drug administration ( Figure 5 ). In addition, we describe other successful applications of this protocol, useful for further molecular characterization of cerebral microvessels, such as the determination of DNA methylation status by isolation of genomic DNA, bisulfite treatment and methylation specific PCR ( Figure 6 ), as well as the extraction of chromatin and shearing to the appropriate size for chromatin immunoprecipitation (ChIP) assays ( Figure 7 ). Finally, we have recently published a study using the described protocol, in which quantitative changes in subcellular localization of tight junction proteins in cerebral microvessels from endothelial-specific genetically engineered mice and correlation with in vivo blood brain barrier and neuronal function are demonstrated 19 . . This protocol will be of great use to researchers intending to understand the molecular mechanisms governing cerebrovascular dysfunction in disease models, or the study of the activation of signaling pathways and intercellular interactions in the cerebral microvasculature in vivo. Ultimately, these studies will aid the development of novel therapies targeting the endothelium to mitigate the progression and/or exacerbation of neuronal injury in cerebrovascular and neurodegenerative diseases.
Development of the protocol and comparison with other methods
To isolate cortical microvessels, we initially used the protocol described by Wu et al., 14 .
While the protocol produced consistent samples in terms of microvessel size and cellular composition, it calls for an enzymatic digestion step. Although samples would potentially be suitable for immunostaining and some biochemical analyses, application of exogenous enzymes and incubation at 37°C cause undesirable molecular and metabolic changes and compromise the integrity of RNA (data not shown). On exclusion of the digestion step, samples contained unwanted debris, as assessed from low-power brightfield images, whereby cellular debris and detached cells could easily be observed. In order to increase the purity of the preparation without the use of enzymatic digestion, we employed an additional wash step (Procedure Step 7) and optimized the dissection and homogenization processes. In order to speed up and optimize the dissection process, we found that gently rolling the brains on blotting paper enabled swift and very efficient removal of the meninges compared to the use of forceps. This technique, which was described in an endothelial cell isolation protocol by Ruck et al. 11 , considerably shortened the dissection process. In addition, we found that consistent tissue homogenization technique is essential in producing samples of similar composition and containing minimal debris. While existing protocols recommended mincing brain tissue into small pieces and using between three (3) and 20 strokes (1) using Dounce homogenizer 14, 16 , we found that 10 strokes without cutting tissue is enough to homogenize cortices and obtain pure microvessel preparations of consistent cellular composition ( Figure 2 ). This modification shortens the time of preparation and therefore, it is critical to preserve microvessel integrity and prevent RNA degradation.
After optimization of our protocol to obtain pure microvessel preparations of consistent cellular compositions, the next critical factor for the molecular characterization and quantification of changes in gene expression is the quality of the RNA. Therefore, we used RNA quality as the ultimate benchmark in reaching our optimized protocol and next, examined the impact of the microvessel isolation method on RNA integrity. We compared the RNA integrity of microvessel preparations conducted in two different conditions. In one condition, every reagent, tools and equipment were kept on ice but the isolation was performed at room temperature, as previously described 16 . In another condition, all steps (from the dissection of the brain to the final step) were conducted in the cold room. Interestingly, we found dramatic changes in the RNA integrity of the microvessel preparations obtained by following these two experimental protocols. As shown in Figure 3a , RNA from microvessels isolated at room temperature was partially degraded as assessed by the integrity number (RIN, 5.2). In contrast, the RNA quality was dramatically increased and RNA showed no degradation (RIN, 10) when microvessels were isolated in the cold room (Fig. 3b) . We then tested how RNA integrity can affect the reliability of results. We chose the Sphingosine-1-phosphate receptor 2 (S1pr2) gene, since we have previously shown that S1PR2 is a low abundance transcript in the endothelium (1-5 mRNA copies/cell) 18 , and therefore particularly difficult to study in terms of generating consistent results if RNA integrity is compromised.
cDNAs were synthesized using RNA isolated from microvessel preparations with RIN ≥9.8 or RIN ≤5.0 and the delta Ct value of each sample to average value of the group was calculated (Fig. 3c) . We found that the coefficient of variation between the preparations was 18.8% when RIN ≥9.8, and as high as 106.2% when RIN ≤5.0.
Altogether these data indicate that the method of microvessel fraction preparation has a great impact on the integrity of the RNA preparation, which is critical for the accurate quantification of low abundance transcripts.
In summary, we found that compared to previously published protocols, the optimizations of the method described here (i.e. dissection and homogenization techniques, the absence of an enzymatic digestion step and the fact that the entire protocol is conducted at 4 o C in the cold room) have a significant impact on the purity and the integrity of the preparation, the consistency of the cellular composition and the quality of the RNA, which significantly affects sample-to-sample variation ( Fig. 1) and as a result, the ability to detect changes in gene expression in disease models or upon pharmacological treatments. In addition, we provide a detailed protocol for the successful isolation of RNA, protein, genomic DNA and chromatin from cerebral microvessels for their molecular characterization.
Applications of the method
Our studies have focused on assessing changes in gene expression or phosphorylated signaling protein levels in disease models or after drug administration. We have shown that this protocol can be used to quantitatively detect changes in gene expression in low abundance and high abundance transcripts in cerebral microvessels in a mouse model of ischemic stroke (Fig. 4) . The protocol can also be used to detect changes in protein phosphorylation upon drug administration in vivo, which allows the investigation of the activation of signaling pathways in the cerebral microvasculature in vivo (Fig. 5 ). In addition, genomic DNA isolated from microvessels using this protocol can be used to detect the DNA methylation status by methylation-specific PCR after bisulfite treatment (Fig. 6 ). Bisulfite treated DNA can be used for further methylation analysis such as pyrosequencing or large-scale bisulfite sequencing. Finally, we have shown that chromatin can be extracted from microvessels after crosslinking with 1% methanol free paraformaldehyde and sheared to the appropriate size (Fig. 7) , and hence, it could be subjected to chromatin immunoprecipitation (ChIP) assay and further analysis such as ChIP-Seq.
In sum, RNA, protein and DNA extracted from microvessels using the described protocol is suitable for use in many different molecular biology and biochemical assays in which the quality of material used is of vital importance in producing reliable and reproducible data.
Experimental design
Each microvessel isolation procedure should include control and experimental groups conducted simultaneously to minimize any variation between procedures. The protocol In addition, every preparation should be examined for 1) purity and structural features such integrity and size distribution, 2) consistency in the cellular composition of endothelial cells, pericytes and astrocytes, and 3) RNA integrity for gene expression analysis.
The purity and structural features of the microvessel preparations can be examined using a bright field microscope. When the procedure is performed successfully, microvessels should retain their structure as shown in Figure 2a , and brain debris, myelin, white matter and single cells should not be observed in the final preparation. In addition, we encourage evaluating the size distribution of isolated microvessels, when first following the protocol. We found that the majority (~90%) of microvessels isolated as described in this protocol are < 5 µm in diameter, 4.1% between 5-10 µm, 5.6% 10-30 µm, and 1% 30-50 µm (Fig. 2b) .
The cellular composition of microvessels can be analyzed using immunofluorescence staining, quantitative real-time PCR and Western blotting. We have found that microvessels isolated using this protocol retain consistent composition, as assessed by immunofluorescence staining using antibodies for specific blood brain barrier cellular components including: endothelial cells (e.g. CD31), pericytes (platelet-derived growth factor receptor-beta, PDFGRβ), and astrocytic end feet (aquaporin 4, AQP4) ( Fig. 2c-h ).
In addition, it is critical to confirm consistency of the cellular composition between preparations by measuring the expression levels of marker genes for these components Lastly, when microvessels are to be used to determine changes in RNA expression between experimental groups, every RNA sample isolated should be tested for RNA integrity. We have demonstrated that RNAs can be easily degraded during the procedure (Fig. 3) ; it is a long process relative to routine whole tissue harvesting and pulverization for RNA extraction, which prolongs the time that microvessels are exposed to endogenous RNases. While we found that performing the entire procedure at 4 °C protects RNA degradation very effectively ( Fig. 3) , we strongly recommend to examine RNA integrity for every sample before proceeding for further analysis. We used a
BioAnalyzer to test RNA integrity, as it gives the quantitative values (RIN 1 to RIN 10), and only requires a small amount of RNA for each assay, but alternative methods such as gel electrophoresis may be used if BioAnalyzer is unavailable.
Level of expertise needed to implement the protocol
Regarding the level of expertise needed to implement this protocol, it is important to consider that the isolation of microvessels requires dissection of the mouse brain. While a microscope is not necessary for the dissection, competent handling of forceps and other appropriate dissecting tools is required to cleanly and swiftly separate the brain from the skull, and to remove the cortex from the deeper structures of the brain. Further to dissection skills, a person who has both some general rodent handling experience, as well as familiarity with basic biological techniques (such as preparation of solutions) and equipment (such as the centrifuge) should be able to conduct the procedure competently with 2-3 practice experiments. As reference, in order to get intact preparations, the entire protocol needs to be completed in 90-120 min.
Advantages and limitations of this approach
The key advantages of the proposed method for the isolation of cerebral microvessels are the following:
This method permits the quick isolation of cortical microvessel fragments of consistent cell composition without the need of enzymatic digestion, thereby preserving RNA integrity. Therefore, it enables quantification of changes in gene expression (even low abundance transcripts or pre-mRNA) in disease models, upon in vivo pharmacological treatments, or genetic deletion in mice.
Due to the high integrity and cellular consistency of the preparations obtained using this method, additional molecular studies can be conducted to gain mechanistic insights into the molecular mechanisms governing these changes in gene expression.
We provide detailed protocols for the determination of methylation status of specific gene promoters and chromatin isolation and shearing.
Since protein post-translational modifications are also retained (e.g. 
MATERIALS REAGENTS
Mice and drug administration
• Adult C57BL/6J mice (6-week-old to 4 month old) and S1pr2 null mice 20 .
!CAUTION All animal experiments should be conducted in accordance with the relevant institutional guidelines and regulations. Our protocol for the use of laboratory animals was approved by Weill Cornell Medicine Institutional Animal
Care and Use Committee.
• JTE013 (Cayman Chemical. cat. no. 10009458)
Microvessels isolation
• 10x PBS (Thermo Fisher, cat.no. 14190250)
• Dextran, molecular weight (MW) ~70,000 Da (Sigma-Aldrich, cat. no. 31390)
• MCDB 131 Medium, no glutamine (Thermo Fisher, cat. no. 10372019)
• Falcon TM Cell Strainer (Corning Inc. cat. no. 352340)
• Fatty acid free BSA, protease-nuclease free (Millipore Sigma, cat.no.126609)
• LiberaseTM (Roche, cat.no. 5401135001)
Immunofluorescence staining
• Paraformaldehyde (Sigma Aldrich. cat. no. P6148) !CAUTION Paraformaldehyde is classified as a known cancer hazard. It should be handled only in a working chemical fume hood with personal protective equipment (PPE) such as lab coats, gloves and face shields.
• 1N NaOH (Fisher Scientific. cat. no. SS266-1)
• 1N HCl (Fisher Scientific. cat. no. SA48-1)
• Bovine serum albumin (Fisher Scientific. cat. no. BP-1605)
• Anti-CD31(Dianova, cat.no. DIA-310)
• Anti-Aquaporin 4 (Sigma-Aldrich. cat.no. A5871)
• Anti-PDGFRb (R&D system, cat.no. AF1042-SP)
• DAPI (Sigma-Aldrich, cat.no. D9542)
• VECTASHIELD Antifade Mounting Medium (Vector Labs. cat.no. H1000)
RNA isolation
• Diethyl pyrocarbonate (Sigma-Aldrich, cat. no. D5758)
• β-mercaptoethanol (Bio-Rad, cat.no. 1610710) !CAUTION β-mercaptoethanol is toxin on inhalation and contact with skin. It should be handled only in a working chemical fume hood with personal protective equipment (PPE) such as lab coats, gloves and face shields.
• Shredder (Qiagen, cat. no. 79654)
• RNase free DNase set (Qiagen, cat.no. 79254)
• RNeasy Mini Kit (Qiagen. cat. no. 74106) cDNA synthesis and quantitative PCR
• Verso cDNA (Thermo Fisher, cat.no. AB1453B)
• PerfeCTa SYBR Green Fast Mix, Low ROX (Quanta Bio, cat.no. 95074)
• 1M Tris-HCl, pH 8.0 (Boston BioProduct. cat.no. BM-320)
• 0.5M EDTA, pH 8.0 (Boston BioProduct. cat.no. BM-150)
Western Blot
• BCA kit (Pierce, cat. no. 23227)
• Protease Inhibitor Cocktail Set I (CalBiochem, cat. no. 539131)
• Spectra™ Multicolor Broad Range Protein Ladder (Thermo Fisher cat. no.
26634)
• 1M HEPES Buffer, pH 7.3 (Fisher Scientific. cat. no. BP299100)
• Triton X-100 Detergent (Bio-Rad. cat. no. 1610407)
• Sodium deoxycholate (Sigma-Aldrich. cat. no. D6750)
• Sodium dodecyl sulfate (Fisher Scientific. cat. no. BP166-100)
• 5M Sodium chloride (Promega Corporation. cat. no. V4221)
• Magnesium chloride solution, 1M (Sigma-Aldrich. cat. no. M1028)
• β-glycerophosphate disodium salt hydrate (Sigma-Aldrich. cat. no. G6251)
• Sodium orthovanadate (Sigma-Aldrich. cat. no. S6508)
• Sodium fluoride (Sigma-Aldrich. cat. no. 215309)
• 4-15% Precast Protein Gels (Bio-Rad. cat. no. 4561084)
• 10x Tris/Glycine Buffer for Western Blots (Bio-Rad. cat.no.1610771)
• 10x Tris/Glycine/SDS (Bio-Rad. cat.no.1610772)
• TBS buffer (Bio-Rad. cat.no.170-6435)
• Tween20 (Fisher Scientific. cat. no. BP337-100)
• Immobilon-P Membrane, PVDF, 0.45 µm (Millipore. cat. no. IPVH00010)
• ECL Western Blotting Substrate (Pierce. cat. no. 32106)
• Blue Autography film (Crystalgen. cat. no. CGFB-507)
• Monoclonal Anti-β-Actin antibody (Sigma-Aldrich. cat. no. A5316)
• Phospho-Akt (Ser473) (193H12) Rabbit mAb (Cell Signaling Technology. cat. no.
4058)
• Chromatin Shearing
• RNase A (Sigma-Aldrich, cat.no. R4642)
• Proteinase K (Roche, cat. no. 50-100-3393)
• truChIP Chromatin Shearing Kit with Formaldehyde (Covaris. cat. no. 520155)
• PCR purification kit (Qiagen, cat. no. 28104)
EQUIPMENT
• Dounce tissue grinder set (Sigma-Aldrich. cat. no. D9063)
• 14 mL round bottom tubes (Nunc TM . cat. no. 150268)
• Ultracentrifuge (SORVALL, model RC-5C Plus, Rotor: 05-SS-34)
• Microcentrifuge tube
• Surgical fine forceps (Fine Science Tools. cat. no. 11271-30)
• Petridish
• Inverted light microscope (Olympus. model CKX41)
• Freezer
• Shaker
• Rotator
• Fume hood
• Superfrost Microscope slides (Fisher Scientific. cat. no. 12-550-123)
• Cover glasses (Fisher Scientific. cat. no. 12-544-12)
• Confocal laser scanning microscope (Olympus, model. FV10i)
• Real-time PCR system (Applied Biosystems. model. ABI 7500 Fast)
• Pulsing Vortex Mixer (Fisher Scientific. model. 02-215-375)
• BioAnalyzer 2100 (Agilent)
• Sonicator (Fisherbrand™ Q55 Sonicator. model FB50)
• Gel documentation system (Bio-Rad)
• Covaris M220
• microTUBE Sap-Cap AFA Fiber (Covaris)
REAGENT SETUP S1pr2 null mice Mice carrying targeted description of the S1pr2 gene are maintained on a mixed mixed C57BL/6;129Sv genetic background (five times backcrossed to C57BL/6) 20 . Wild-type littermates should be used as controls for experiment on S1pr2 knockout (KO) mice.
JTE013 stock solution Dissolve JTE013 in DMSO at a final concentration of 100 mM.
Make sure that it completely goes into solution. Aliquots can be stored up to 6 months at -20 °C. 4) Homogenize cortical tissue using a loose fit, 7 ml Dounce tissue grinder. Perform an initial 10 strokes in 1 ml MCDB 131 medium at a steady pace, without twisting the pestle.
JTE013 gavage administration
5) Add 7 ml of MCDB131 medium to homogenate from step 4 and perform additional 2 strokes in a total of 8 ml.
6) Pour homogenized tissue into a 14 ml round-bottom centrifuge tube. Take care to alter the volumes using additional MCDB 131 medium, so that each sample is evenly balanced.
7) Centrifuge at 2,000 g for 5 mins, 4 °C. Pour out supernatant and rest the inverted tube on a paper towel, to absorb excess medium/debris clinging to the sides.
w CRITICAL STEP This is a wash step, and helps with the removal of small pieces of white matter debris that have remained attached to the sample.
8) The pellet must be resuspended in 15 % dextran/PBS.
A. In order to dissociate the pellet evenly, add an initial 1 ml dextran solution to the pellet, and use it to sluice the pellet gently from the side of the tube.
B. Resuspend the floating pellet with 5-6 steady uses of the pipet, taking up the entire pellet with each use.
C. Add a further 7 ml dextran solution and balance with additional dextran solution.
9) Centrifuge at 10,000 g for 15 mins, 4°C. The red, microvessel-containing pellet will appear.
w CRITICAL STEP If pellet does not appear to be in clean red color, it indicates contamination with white matter, myelin or debris.
? TROUBLESHOOTING
10) The supernatant should be removed carefully to avoid contaminating the pellet with debris. Begin by pipetting off the top, brain tissue-containing layer completely, then aspirating the underlying solution, which will contain a small amount of debris.
11) Remove the pellet using 1 ml PBS. Sluice the pellet from the side of the tube, and take up into the pipet tip with the absolute minimum of PBS that has passed into the tube.
w CRITICAL STEP Using more than 1 ml of PBS is discouraged. You will see some of debris on the wall of tube that can be easily taken by pipetting. Using small volume is beneficial to minimize the contamination.
12) Transfer the pellet onto a 40 µm cell strainer, and wash through with <10 ml PBS.
This step is intended to remove debris that has remained slightly adhered to the microvessels as well as loose debris.

13)
Reverse the filter and retrieve the microvessels using 10 -20 ml of MCDB 131 medium containing 0.5% fatty-acid, protease-, and endotoxin free BSA.
Bright field and phase contrast Image
To quickly evaluate purity of microvessels by microscopic method, take 50 ul of microvessels suspension from step 13, and plate onto a 35 mm culture dish for 5 mins at room temperature. Once microvessels attaché to the surface of the dish, observe under inverted microscope.
2)14) Centrifuge at 5,000 g for 10 mins, 4°C. This will yield the final microvessel pellet.
? TROUBLESHOOTING ? TROUBLESHOOTING
Troubleshooting advice can be found in Table 2 .
Timing
Microvessels isolation (90 -120 min)
Steps 1-3, euthanasia and dissection of the brain: 5-7 min per mouse
Steps 4-7, homogenization cortices and centrifugation: 20 min
Step 8, removal of supernatant and re-suspending pellet in dextran: 10-15 min
Step 9-13, centrifugation and retrieval of microvessels pellet: 30-40 min
Step 14, final centrifugation and resuspend in proper lysis buffer: 15-20 min
Analysis of microvessels
A. Immunofluorescence characterization Timing 24 h
i. Add 8 ml of 4% PFA/PBS into a 35 mm petridish.
ii. Submerge the cell strainer containing microvessels from step 12 into 4 % PFA/PBS and fix microvessels for 15 mins with gentle shaking.
iii. Place the cell strainer on a 50 ml tube and wash through with 10 ml of PBS.
iv. Reverse filter on another 50 ml tube, and collect microvessels by thoroughly applying 15 -20 ml of 1% BSA/PBS onto the surface of the filter.
v. Centrifuge the suspension at 2,000 g for 10 mins, 4 °C.
vi. Aspirate and discard the 1 % BSA/PBS and resuspend pellet in 400 µl of PBS.
vii. Drop 50 µl of suspension onto a Superfrost microscope slides and air dry slides.
It takes about 30 mins.
nPause Point Slides can be stored at -80 °C for up to 12 months before processing.
viii. Wet the microvessels with 1x PBS for 10 mins.
ix. Permeablize the microvessels with 0.1 % NP40/PBS for 15 mins.
x. Block the microvessels with 5% BSA/PBS for 1 hr.
xi. Incubate the microvessels overnight at 4°C with the primary antibodies CD31
( 
B. RNA isolation Timing 2-3 h
i. After centrifugation from step 14, discard supernatant and quickly remove residual medium by inverting the tube on a paper towel.
ii. Add 700 µl of RLT buffer provided from RNeasy Kit (Qiagen).
iii. Resuspend microvessels pellet in RLT buffer with 20 -25 times of pipetting and vigorous vortexing for approximately 30 sec to completely disrupt microvessels.
iv. Snap freeze in liquid nitrogen and store at -80 °C up to 6 months.
nPause Point Lysate can be stored at -80 °C before processing v. Isolate RNA according to instruction from Qiagen and include DNaseI treatment step as described in manufacturer's instruction.
vi. Measure RNA integrity by BioAnalyzer.
u CRITICAL STEP RNA integrity should be tested prior to downstream analysis of mRNA.
C. Protein extraction Timing 2 h
i. After centrifuge from step14 discard supernatant by converting the tube containing pelleted microvessels and stand on paper towel for a few second.
i.ii. Add 80 µl of ice-cold protein lysis buffer (50 mM HEPES pH 7.5; 1% Triton; 0.5% sodium deoxycholate; 0.1 % SDS; 500 mM NaCl; 10 mM MgCl 2 ; 50 mM β-glycerophosphate; 1x Protease inhibitor cocktail; 1 mM Na 3 VO 4 ; 1 mM NaF) u CRITICAL STEP Add protease inhibitor cocktails and phosphatase inhibitors (Na 3 VO4 and NaF) to protein lysis buffer fresh before use.
iii. Sonicate pelleted microvessels for 3 x 5 seconds at 50 amplitude using a probe type sonicator on ice.
iv. Vortex lysate under maximum speed for 15 mins, 4 °C. This step will help lyse microvessels adequately.
u CRITICAL STEP Keep the tip of probe to avoid foaming during sonication.
v. Centrifuge lysate at 10,000 g for 10 mins, 4 °C and transfer supernatant into a new tube.
nPause Point Protein can be stored at -80 °C up to 6 months before processing.
vi. Measure protein concentration using bicinchoninic acid (BCA) assay according to manufacturer's instruction. We normally obtain 150-160 µg of protein from one brain.
D. Crosslinking and chromatin shearing Timing 24 h
Note: We used a commercially available kit, truChIP TM Chromatin Shearing Reagent Kit ii. Transfer the cell strainer containing washed microvessels from step 12 to petridish and incubate for 5 mins at room temperature with gentle shaking.
u CRITICAL STEP Make sure the strainer submerged completely into 1% methanol free PFA solution during the crosslinking.
iii. Add quenching buffer provided from the kit as described in manufacturer's instruction to stop crosslinking.
iv. After a brief wash with 2ml of PBS, retrieve fixed microvessels from the strainer with 10 ml of 1% BSA/PBS, and centrifuge at 2,000 g for 10 mins.
v. Discard supernatant and resuspend the pellet in the lysis buffer B provided from the kit. We combine microvessels from two brains in 300 µl of lysis buffer B.
nPause Point Microvessels pellet can be stored at -80 °C before processing up to 6 month.
vi. Incubate lysate for 15 mins, 4 °C on a rotator and transfer lysate to the microTUBEs.
vii. Set the CovarisM220 at 5 % duty factor, 50 P.I.P, 200 cpb, and sonicate lysates for 3 mins.
u CRITICAL STEP We incorporated a mild sonication steps due to difficulties of pulverizing microvessels. To maximize yield of chromatin extraction, it is critical to disrupt and lyse microvessels properly and completely. After step vii, the structure of microvessels should not be visible.
viii. Centrifuge lysate from step vii at 1,700 g for 5 mins, 4 °C.
ix. Add 600 µl of wash buffer provided from the kit and incubate for 5 mins on a rotator, 4 °C, followed by centrifugation at 1,700 g for 5 mins to collect nuclear extract.
x. Resuspend pellet in 550 µl of shearing buffer that provided from the kit, and vortex until it is mixed.
xi. Transfer chromatin to the microTUBE and sonicate with the default setting of Low Cell Chromatin Shearing Protocol for M-Series as described in manufacturer's instruction for 4 or 8 mins.
xii. Process sheared chromatin according to manufacturer's instruction to check the size of sheared chromatin by electrophoresis using 2 % agarose gel or by BioAnalyzer.
ANTICIPATED RESULTS
A. Quantification of changes in gene expression
First, we aimed to determine whether the isolated microvessels retained the expected molecular changes in the brain vasculature in a disease model, namely, the transient middle cerebral artery occlusion (tMCAO) mouse model of ischemic stroke. 2-month-old C57/Bl6 mice were subjected to sham surgery or transient focal ischemia (tMCAO) for 45 mins as we previously described 18 . 24 hours after reperfusion, cortical microvessels were isolated from the ischemic hemisphere (ipsilateral). Ipsilateral cortices from two mice were pooled.
RNA was isolated from microvessels of each group, and levels of gene expression were quantified by reverse transcription and quantitative real time PCR. The primer sequences used for analysis are indicated in Table 1 . As shown in Figure 4 , consistent with previous reports, the endothelial pro-inflammatory gene, E-Selectin and the astrocyte activation marker, Gfap, were significantly upregulated in cerebral microvessels in the ipsilateral cortex compared to the contralateral (57.9±14.8-fold and 5.1±0.8-fold induction, respectively). We also aimed to investigate if changes in S1pr2 mRNA, one of the receptors for the bioactive lipid sphingosine-1-phosphate (S1P) 21 , could be detected in cerebral microvessels in vivo. We recently showed that S1pr2 expression increases upon ischemia-reperfusion (I/R) injury in mouse brain and in vitro in endothelial cells 18, 22 , Consistent with these studies, S1pr2 mRNA expression was increased 2.4±0.2-fold in cortical microvessels upon I/R injury. In addition, we tested the levels of S1PR2 pre-mRNA levels, which is normally less abundant than mature mRNA.
We found that S1PR2 pre-mRNA levels were also increased 2.1±0.4-fold in microvessels in response to I/R injury, suggesting that S1PR2 is regulated at the transcriptional level upon I/R injury. The levels of the endothelial tight junction protein zonula occludens 1 (Zo-1), were not changed (Fig. 4) , as well as the astrocyte and pericyte markers (aquaporin 4 and Cd13, respectively, not shown), indicating that the cellular composition was similar between preparations.
B. Phospho-protein changes
Given the relative difficulties in measuring changes in protein phosphorylation in vivo, we tested if our microvessel isolation protocol was suitable to capture these changes. We and others have previously shown that S1P, which is very abundant in plasma and it is produced and released mainly by endothelial cells, erythrocytes and platelets 23 , activates S1PR2 in the endothelium giving rise to inhibition of Akt phosphorylation (Ser473) via the Rho-Rho dependent kinase (ROCK)-Phosphatase and tensin homolog (PTEN) pathway [24] [25] [26] . Therefore, we aimed to compare phospho-Ser 473-Akt levels in cortical microvessels of mice bearing genetic deletion of the S1pr2 gene or upon acute inhibition of S1PR2 signaling by administration of the S1PR2 antagonist JTE013. We first compared Akt phosphorylation levels in microvessels isolated from S1pr2 -/-brain cortex with wild type. As shown Figure 5A , we found that phospho-Akt levels were significantly higher in S1pr2 null mice compared to their wild type littermates (2.9±0.29 fold). In addition, phospho-Akt levels were also significantly increased (1.5±0.05 fold) in cerebral microvessels 6 h after administration of JTE013 (30 mg/kg) by gavage. These data are consistent with our previous in vitro signaling studies in endothelial cells 24, 27 and indicate that the method described allows the quantification of changes in protein phosphorylation, and thus, it can be used to conduct signaling studies in the brain microvasculature in vivo.
C. Assessment of DNA methylation
We also tested if genomic DNA isolated from microvessels can be used to detect epigenetic modifications such as methylation of gene promoters. Primers to detect specific methylated or un-methylated DNA were designed using MethPrimer (http://www.urogene.org/methprimer/) and are shown in Table 1 . Genomic DNA (gDNA) isolation, bisulfite treatment, and methylation specific PCR were performed according to manufacturer's instruction. We first tested promoter IX of brain derived neurotrophic factor (Bdnf) gene since it has been shown to be methylated in adult mouse brain 28 . We isolated gDNA from microvessels as well as whole brain of adult mice and treated with bisulfite. Then, PCR was conducted with primers to detect methylated or un-methylated DNA ( Table 1) . As shown in Figure 6 , we were able to detect methylation of Bdnf promoter IX while no bands were amplified with the primers to detect unmethylated DNA. These data indicate that Bdnf promoter IX is methylated in both in brain as well as in cerebral microvessels, consistent with previous reports 28 . We then tested the methylation status of S1pr1 and S1pr2 CpG islands in their core promoters. The information of genomic features including core promoter regions and CpG island was obtained from Ensemble (http://www.ensembl.org) and Genome Browser (https://genome.ucsc.edu). Interestingly, we found that both S1pr1 and S1pr2 CpG islands were unmethylated, which is consistent with the expression of S1PR1 and S1PR2 in the cerebrovascular endothelium. These data indicate that microvessels can serve as a useful material to detect genomic DNA methylation. As described earlier, the bisulfite treated gDNA can be subjected to pyrosequencing to quantify the degree of methylation in CpG islands of the specific gene promoters or to bisulfite whole genome sequencing to discover a broad range of methylation status which should generate valuable information to understand mechanism of regulation in gene expression 29 .
D. Optimization of chromatin extraction and shearing from cortical microvessels
ChIP assay is a very valuable technique to determine histone modifications as well as binding of proteins (e.g. RNA polymerases, transcription factors) to specific regions of the chromatin both in vitro and in vivo. However, when conducting ChIP assays in tissues, chromatin extraction and shearing to the adequate size it is one of the major challenges. The type and concentration of fixative, crosslinking and sonication conditions need to be optimized for each specific tissue. We used a commercially available kit to extract chromatin from cortical microvessels and described the optimized method to isolate and shear chromatin fragments for ChIP assays. In particular, it is critical to properly disrupt the tissue to extract chromatin completely, which generally can be done by pulverizing frozen tissue in liquid nitrogen using mortar and pestle. Due to the challenges of pulverizing a small pellet of microvessels, we first incubated the microvessel preparation in lysis buffer alone, as recommended by the manufacturer's instructions. However, this procedure was insufficient to completely disrupt them, as it was assessed by the presence of visible structure of intact microvessels in the lysate (Figure 7a ). In addition, incomplete disruption yielded very low amount of chromatin. However, when we incorporated a mild sonication step after incubation in lysis buffer, the lysate turned cloudy without any visible intact microvessels (Fig. 7b) resulting in a dramatic increase in the yield.
In addition, we have tested various conditions for crosslinking and sonicating the extracted chromatin and we found that crosslinking with 1% methanol-free formaldehyde for 5 mins, and sonication for 4-8 mins gives rise to 200-400 bp chromatin fragments ( Fig. 7c-e) , which is the optimal shearing size for most applications.
The condition we provide here may need to be further optimized depending on the levels of expression and the location of the specific DNA binding protein to be pulled down and/or the genomic region/s involved 30 . However, our data indicate that the sheared chromatin obtained with the provided protocol is suitable for ChIP assay and whole genome sequencing. Changes in Zo-1, S1pr2, glial fibrillary acidic protein, E-Selectin mRNA (Zo-1, S1pr2,
Gfap and E-Selectin, respectively), as well as S1pr2 pre-mRNA levels (S1pr2 pre- 
